正在加载公司
Just reported
From Sanara Medtech's results release of 2026年11月12日; its quarterly report has since been filed.
Actual
US$28.4M
+8.0% y/y
+1.0% q/q
Guided
—
No guide given
Actual
US$736K
-75% y/y
-59% q/q
Guided
—
No guide given
Q3 2026
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Sanara Medtech is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.US$153.8BA+
MDLNMedline Inc.US$51.9BA
ALCAlcon Inc.US$36.1BA
BLCOBausch & Lomb CorpUS$7.5BA-
ATRCAtriCure, Inc.US$2.9BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
GEHCGE Healthcare Technologies Inc.2026年10月28日CAGraded C, now A基于 Sanara Medtech Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
公司指引：2026 财年营收 US$110M 至 US$115M — 同比增长 9.1%
Grade B-
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Sanara Medtech Inc. 评级历史 40 个季度中的 2 个。 其余 38 个可回溯到 2016年11月。
